PTGX241220C12500
- 18.60
- 0.000.00%
Protagonist Therapeutics Newsroom
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
BTIG Downgrades Protagonist Therapeutics(PTGX.US) to Hold Rating, Raises Target Price to $67
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $65
A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $50 to $65
TD Cowen Remains a Buy on Protagonist Therapeutics (PTGX)
Protagonist Therapeutics Analyst Ratings
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $60
Protagonist Therapeutics Analyst Ratings
BTIG Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $51
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $50
J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $51
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $65
Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $58
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $65
Positive Outlook and Buy Rating for Protagonist Therapeutics Based on Promising Phase III Results and Strategic Positioning
Wedbush Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $58
Protagonist Therapeutics Price Target Announced at $58.00/Share by Wedbush
Protagonist Therapeutics Analyst Ratings